A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

NCT06987500 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor, Solid

Interventions

DRUG: XNW29016
DRUG: XNW29016

Sponsor

Evopoint Biosciences Inc.

Collaborators

[object Object]